Dr. LAURA CUBAS NÚÑEZ

NEUROINMUNOLOGY UNIT · NEUROIMMUNOLOGY UNIT

Neuroimmunology Unit. La Fe Health Research Institute. Valencia, Spain.

Author

APID

5545

ORCID

0000-0003-4934-3891

Scopus

57191970497

Location

VALENCIA, VALENCIA, SPAIN

Expertise

DEMYELINATING DISEASES

Areas of interest

MULTIPLE SCLEROSIS

Member since

January 2024

Publications

1. Early Alzheimer's Disease Screening Approach Using Plasma Biomarkers
2. Early Alzheimer's Disease Screening Approach Using Plasma Biomarkers
3. Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.
4. Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.
5. High Levels of Cerebrospinal Fluid Kappa Free Light Chains Relate to IgM Intrathecal Synthesis and Might Have Prognostic Implications in Relapsing Multiple Sclerosis.
6. High Levels of Cerebrospinal Fluid Kappa Free Light Chains Relate to IgM Intrathecal Synthesis and Might Have Prognostic Implications in Relapsing Multiple Sclerosis.
7. Improving the efficiency of free kappa light chains as diagnostic biomarker of Multiple Sclerosis by using a novel algorithm.
8. Improving the efficiency of free kappa light chains as diagnostic biomarker of Multiple Sclerosis by using a novel algorithm.
9. Is it cost-effective to request IgM oligoclonal bands against lipids in daily practice as a biomarker for poor prognosis in multiple sclerosis?
10. Is it cost-effective to request IgM oligoclonal bands against lipids in daily practice as a biomarker for poor prognosis in multiple sclerosis?
11. NFL during acute spinal cord lesions in MS: a hurdle for the detection of inflammatory activity.
12. NFL during acute spinal cord lesions in MS: a hurdle for the detection of inflammatory activity.